BIODESIX INC — Director's Dealing 2022

Mar 14, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIODESIX INC (BDSX)
CIK: 0001439725
Period of Report: 2021-02-23

Reporting Person: Hutton Scott (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-23	Stock Options (Right to buy)	$0.77	A	8423	Acquired	2029-03-21	Common Stock (8423)	Direct
2022-03-10	Stock Options (Right to buy)	$0.77	A	8423	Acquired	2029-03-21	Common Stock (8423)	Direct
2022-03-10	Stock Options (Right to buy)	$2.29	A	85875	Acquired	2032-03-09	Common Stock (85875)	Direct

Footnotes

F1: On March 22, 2019, the Reporting Person was granted an option to purchase 25,269 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 8,423 shares underlying the option.

F2: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 8,423 shares underlying the option.

F3: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 8,423 shares underlying the option.